A detailed history of Goodman Advisory Group, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Goodman Advisory Group, LLC holds 8 shares of NTLA stock, worth $117. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8
Previous 8 -0.0%
Holding current value
$117
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 03, 2022

BUY
$38.49 - $76.21 $307 - $609
8 New
8 $0

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.12B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Goodman Advisory Group, LLC Portfolio

Follow Goodman Advisory Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goodman Advisory Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Goodman Advisory Group, LLC with notifications on news.